Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04424641 · ClinicalTrials.gov registry record · Phase 1
A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors
A Phase 1 study, sponsored by Genmab.
- Terminated
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT04424641 is a Phase 1 study that was terminated before completion, run by Genmab. The registered enrollment target is 48 participants.
The verdict
NCT04424641, a Phase 1 study, was terminated before completion, sponsored by Genmab.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
The purpose of the trial is to evaluate the safety, determine the recommended Phase 2 dose (RP2D), and assess preliminary clinical activity of GEN1044 in patients with solid tumors.
Interventions
- BIOLOGICAL GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2020-07-15 |
| Est. Completion | 2021-10-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04424641
The ClinicalTrials.gov registry entry for NCT04424641 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genmab, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4. is the first listed.
NCT04424641 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04424641 about?
NCT04424641 is a clinical study titled "A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant Solid Tumors". The purpose of the trial is to evaluate the safety, determine the recommended Phase 2 dose (RP2D), and assess preliminary clinical activity of GEN1044 in patients with solid tumors.
What is the current status of trial NCT04424641?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2020-07-15. Estimated completion is 2021-10-29.
What interventions are being tested in trial NCT04424641?
The interventions under investigation include: GEN1044 is an immunoglobulin G1 (IgG1) bispecific antibody targeting CD3 and 5T4. (BIOLOGICAL).
Who is sponsoring clinical trial NCT04424641?
This trial is sponsored by Genmab, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.